STOCK TITAN

GLAUKOS (GKOS) SEC Filings, Aug-Oct 2026

GKOS NYSE

Glaukos Corporation filings document the regulatory record for an ophthalmic pharmaceutical and medical technology company with common stock listed on the New York Stock Exchange under GKOS. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary net sales information, supplemental business summaries, and Regulation FD investor presentations.

The company’s proxy materials provide governance and executive-compensation disclosures, including equity-award and pay-versus-performance information. These filings also identify Glaukos as a Delaware corporation and frame disclosure around its glaucoma, corneal-disorder, and retinal-disease therapies, commercial products, risk disclosures, and public-company reporting obligations.

Rhea-AI Summary

GLAUKOS Corp Chief Development Officer Tomas Navratil reported three direct sales of common stock on October 5, 2026: 888 shares at a weighted-average $163.93 per share, 327 at $164.78, and 312 at $165.60. The sales were made under a Rule 10b5-1 trading plan adopted June 12, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
insider
-
Rhea-AI Summary

Tomas Navratil, an officer of Glaukos Corp, gave notice of a proposed sale of 1,527 common shares, with an aggregate market value of $251,121.33. The approximate sale date is October 5, 2026; Fidelity Brokerage Services LLC is listed as broker and NYSE as the exchange.

The past-three-month sales table lists 13,744 shares sold August 28, 2026, for $2,483,097.96; 1,457 shares sold September 16, 2026, for $243,207.31; and 1,615 shares sold September 25, 2026, for $249,157.98.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.48%
Tags
other
-
Rhea-AI Summary

GLAUKOS Corp chief development officer Tomas Navratil reported selling 1,615 common shares on September 25, 2026, across four transactions: 167 shares at a weighted-average $151.70 per share, 136 at $152.71, 229 at $154.24 and 1,083 at $154.88. The sales were made under a Rule 10b5-1 trading plan adopted June 12, 2026; each reported price reflects multiple trades.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.01%
Tags
insider
Rhea-AI Summary

GLAUKOS Corp (GKOS) officer Tomas Navratil reported a proposed sale of 1,615 common shares, with an aggregate market value of $249,157.98 and an approximate sale date of September 25, 2026. Fidelity Brokerage Services LLC is listed as broker, with NYSE as the exchange. Restricted stock vesting on March 22, 2025, is listed as the shares’ source. Earlier reported sales were 716 shares on July 1, 2026, 13,744 shares on August 28, 2026, and 1,457 shares on September 16, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
other
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) reported that its Chief Development Officer, Tomas Navratil, sold a total of 1,457 shares of common stock on September 16, 2026 in a series of open‑market transactions under a Rule 10b5-1 trading plan adopted on June 12, 2026.

The weighted‑average sale prices for the trades ranged from about $163.20 to $172.00 per share, and the officer’s holdings include 38,817 restricted stock units that have not yet vested or been delivered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.39%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) is the issuer for a Rule 144 notice filed on behalf of officer Tomas Navratil covering planned sales of 1,457 shares of common stock. The shares relate to restricted stock vesting events dated March 22, 2025 (709 shares) and March 24, 2025 (748 shares), listed as compensation.

The notice also lists prior open-market sales by Tomas Navratil over the last three months, including transactions on June 16, 2026, July 1, 2026, and August 28, 2026, with share counts and dollar amounts disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
other
Rhea-AI Summary

GLAUKOS Corp (GKOS) reported that chief development officer Tomas Navratil sold a total of 13,744 shares of common stock on August 28, 2026, in three open-market transactions. The sales covered 7,643 shares at a weighted average price of $180.25 (with individual trades between $179.69 and $180.69), 6,091 shares at a weighted average price of $181.19 (with trades between $180.71 and $181.61), and 10 shares at $182.50. The prices reported are weighted averages, and detailed trade breakdowns are available upon request. Following these transactions, Navratil’s equity holdings include 38,817 restricted stock units that have not yet vested or been delivered.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.60%
Tags
insider
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) insider Tomas Navratil, identified as an officer, filed a notice of proposed sale of 13,744 shares of common stock under Rule 144 through Fidelity Brokerage Services LLC. The shares have an aggregate market value of $2,483,097.96. Common shares outstanding were 58,983,937 as of August 28, 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
other
-
Rhea-AI Summary

GLAUKOS Corp (GKOS) director Gilbert H. Kliman exercised stock options for 2,500 shares of common stock on 2026-08-19 at an exercise price of $25.77 per share. The resulting 2,500 common shares were then sold the same day at $190.00 per share. After the exercise, Kliman continued to hold stock options for 12,500 shares, and his equity awards also include 2,501 restricted stock units that are unvested or deferred.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.00%
Tags
insider
Rhea-AI Summary

GLAUKOS Corp (GKOS) is the issuer for a planned resale of its common stock under Rule 144 by shareholder Gilbert H. Kliman. The notice covers the potential sale of 2,500 shares of Glaukos common stock through Fidelity Brokerage Services LLC on or after 08/19/2026 on the NYSE.

The shares to be sold are tied to a stock option exercise for cash, with an aggregate market value listed as $475,000.00. Fidelity signed the notice as attorney-in-fact for Kliman.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.46%
Tags
other

FAQ

How many GLAUKOS (GKOS) SEC filings are available on StockTitan?

StockTitan tracks 174 SEC filings for GLAUKOS (GKOS), including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and Form 4 insider trading disclosures. Each filing includes AI-generated summaries, impact scoring, and sentiment analysis.

When was the most recent SEC filing for GLAUKOS (GKOS)?

The most recent SEC filing for GLAUKOS (GKOS) was filed on November 20, 2026.